Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

From advances in targeted therapies to the integration of AI and steps towards precision medicine, 2024 brought many exciting developments in the field. With 2025 now unfolding, many of these are likely to continue gaining momentum and potentially redefine patient care. In this latest edition of touchREVIEWS in RMD, we’re excited to present a collection […]

Dermatological Conditions

An Introduction to Dermatological Conditions

Supported by:
EU Partner
touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

39 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION
Prof. Dr. med. Diamant Thaçi, Dr Benjamin Ungar

Watch expert dermatologists discuss the management of moderate-to-severe AD in children and adolescents.

52 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION
Prof. Dr Vito Sabato, Dr Sigurd Broesby-Olsen, Prof. Prithviraj Bose

Multidisciplinary experts discuss the diagnosis and management of patients with systemic mastocytosis.

38 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchMDT
Dr Manuel Pereira, Ms Sailaja Maganti, Prof. Anthony Bewley, Prof. Martin Metz

Select a discussion in our hub to watch our multidisciplinary experts, including a patient advocate, share important perspectives on the need to establish patient-centric treatment and care pathways for the management of prurigo nodularis.

8 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Canada, China, Colombia, Costa Rica, Denmark, Dominican Republic, Ecuador, Egypt, Finland, France, Germany, Guatemala, Hong Kong, Hungary, Iceland, Italy, Kuwait, Lebanon, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Singapore, South Korea, Spain, Sudan, Sweden, Taiwan, Thailand, The Netherlands, and UAE

Watch highlights of three ADVENT symposia presented at EADV 2023

38 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION
Dr Elaine Siegfried, Assist. Prof. Nives Pustišek, Prof. Andreas Wollenberg

Watch three experts discuss how they manage moderate-to-severe atopic dermatitis in children.

49 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION
Prof. Sonja Ständer, Dr Shawn Kwatra, Prof. Matthias Augustin

Watch three experts discuss the symptom burden faced by patients with prurigo nodularis, and how clinicians can optimize diagnosis and treatment of the disease. **Now including 2023 UPDATE (scroll to chapter 5)**

5 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Canada, Chile, China, Colombia, Costa Rica, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Lebanon, Macau, Malaysia, The Netherlands, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, and UAE

Key updates from 2 cutting-edge expert symposia presented at WCD 2023

Developed by Touch

Effisayil 1 (NCT03782792) was a randomised, double-blind, placebo-controlled phase 2 study that investigated the efficacy and safety of spesolimab in generalized pustular psoriasis (GPP). touchIMMUNOLOGY were delighted to speak with Dr. Claudia De La Cruz (Clínica Dermacross, Santiago, Chile) to discuss ...

Developed by Touch

Pemphigus is a rare autoimmune blistering disease, which results in painful blisters on the skin or mucous membranes, severely impacting patient quality of life. It was a pleasure to talk with Prof. Dedee F. Murrell (St George Hospital Campus, Kogarah, ...

Developed by Touch

touchIMMUNOLOGY coverage of data presented at AAD 2023: The treatment paradigm for pemphigus remains with many unmet needs, the current standard of care remains to be systemic corticosteroids, which cause many phycological and metabolic side effects, in the past few years ...

Developed by Touch

Dupilumab is a monoclonal antibody approved for use in patients with atopic dermatitis that is not well controlled with topical treatments, or who are unable to use topical treatments. It was a pleasure to talk with Prof Amy Paller (Northwestern ...

Developed by Touch

Atopic dermatitis is a chronic skin disorder causing inflammation, redness and irritation of the skin, and usually begins in childhood. touchIMMUNOLOGY caught up with Prof Amy Paller (Northwestern University Feinberg School of Medicine; Lurie Children's Hospital of Chicago, Chicago, IL, ...

Developed by Touch

TRuE-V1 (NCT04052425) and TRuE-V2 (NCT04057573) were randomized, double-blind, vehicle-controlled phase 3 studies that investigated ruxolinitib cream for the treatment of vitiligo over 52 weeks. We were delighted to speak to Dr. Amit G. Pandya (Palo Alto Foundation Medical Group, Sunnyvale, CA, USA) ...

Developed by Touch

Ruxolitinib cream, a cream formulation of the JAK 1/JAK2 inhibitor was first approved for use in vitiligo by the FDA in July 2022 and is the only topical treatment approved for repigmentation. We were delighted to speak to Dr. Amit G. ...

Developed by Touch

Ixekizumab is a humanized monoclonal antibody currently approved in patients with moderate-to-severe plaque psoriasis. We caught up with Dr Alan Menter (Baylor University Medical Center, Dallas, TX, USA) to discuss the aims, design, inclusion criteria and main findings of a ...

Load More...
Close Popup